Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Inclusion criteria

• ✓. Male and female subjects age 18 years and older who are able to sign informed consent and to comply with the protocol
• ✓. Patients with histologically or cytologically-documented, locally advanced, or metastatic solid tumor malignancy that has either (a) progressed on at least one line of prior standard systemic therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient or treating physician. There is no limit to the number of prior treatment regimens
• ✓. C-1: Patients with primary central nervous system (CNS) tumors and documentation of positive BRAF V600 mutation
• ✓. C-2: Patients with advanced or metastatic solid tumors and documentation of positive BRAF V600 mutation excluding primary CNS tumor
• ✓. C-3: Patients with advanced or metastatic solid tumors and documentation of positive BRAF mutation including primary CNS tumors but excluding melanoma with brain metastasis
• ✓. C-4: Patients with melanoma with brain metastasis and documentation of positive BRAF mutation
• ✓. Must have at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors or the RANO criteria for primary CNS tumors, such as gliomas.
• ✓. ECOG performance status of 0 or 1 or Karnofsky performance status of ≥ 70